Therefore, we aimed to assess whether the elevated levels of miR-19a-3p in the serum of patients with metastatic HER2 + breast cancer and a favorable prognosis were associated with the levels of CD4 + T cells expressing IFN-γ in the peripheral blood. The gene discussed is CD4; the disease is breast carcinoma.